JSJouko Saramies

Jouko Saramies

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jouko Saramies has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Analysis of Skeletal Muscle Transcriptional Networks Characterizes Dysregulation in Pathways and Trait-Associated Regulatory Regions in Type 2 Diabetes

    by Avery Maddox, Nandini Manickam, Peter Orchard, Michael R. Erdos, Narisu Narisu, Heather M. Stringham, Timo A. Lakka, Jouko Saramies, Markku Laakso, Jaakko Tuomilehto, et al.

    Skeletal muscle, a primary site of insulin-mediated glucose uptake, plays a central role in the pathogenesis of type 2 diabetes. It is therefore critical to understand the disease-associated alterations in skeletal muscle and identify the underlying drivers of this dysregulation. Here, we characterize type 2 diabetes associated transcriptional dysregulation using 301 skeletal muscle biopsies from living donors with and without diabetes. Using weighted gene co-expression network analysis, we identify 56 distinct gene modules, which we further characterize using single-nucleus RNA-seq-derived cell type signatures and pathway enrichment analysis. We identify numerous cell type-associated dysregulated pathways in skeletal muscle tissue from individuals with diabetes, including muscle fiber-associated mitochondrial function and mRNA splicing and processing; endothelial vascularization and phospholipase D signaling; and macrophage- and T-cell-associated inflammation. Through analysis of module hub genes and transcription factor regulatory network analysis, we further identify candidate driver genes of this dysregulation including ATP5L , ATF2 , SIRT1, and THRAP3 in muscle fibers; JAM2 and CLEC14A in endothelial cells; and F13A1 and IRF8 in immune cells. Finally, we integrate our co-expression networks with single-nucleus ATAC-seq data to identify proximal and distal genomic regulatory elements and identify context-specific enrichment for type 2 diabetes and related trait GWAS signals in muscle fiber and endothelial modules. Together, our results reveal dysregulation in pathways in muscle tissue from individuals with diabetes, identify candidate drivers, and connect the genomic drivers of this dysregulation across type 2 diabetes and related metabolic traits.

  • Open Access

    Donor-matched iPSC model reveals context-dependent T2D genetic signals in fibro-adipogenic progenitors

    by Christa Ventresca, Arushi Varshney, Peter Orchard, Ha T H Vu, Yao-Chang Tsan, Andre Monteiro Da Rocha, Michael R Erdos, Leena Kinnunen, Timo A Lakka, Jouko Saramies, et al.

    Summary: Fibro-adipogenic progenitors (FAPs) in skeletal muscle have been implicated in type 2 diabetes (T2D), yet their heterogeneity and context-dependent regulation remain poorly understood. Here, we establish induced pluripotent stem cell (iPSC)-derived FAPs as a model of primary FAPs by leveraging a unique resource: iPSC lines and skeletal muscle biopsies obtained from 34 individuals, a subset of 30 profiled using single-nucleus multiomics. Donor-matched comparisons reveal iPSC-FAPs recapitulate the transcriptome, epigenome, and subtype composition of primary FAPs. Using single-nucleus multiomics, we show that high-insulin exposure drives iPSC-FAPs toward an adipogenic fate - and this adipogenic subtype is enriched for T2D GWAS signals, an enrichment undetectable at baseline. We map the T2D-associated rs3814707 non-coding signal to LTBP3 , a gene that influences FAP adipogenic differentiation. These findings reveal how disease-relevant regulatory mechanisms can be masked in unstimulated cells and establish iPSC-FAPs as a powerful platform for dissecting the state-dependent biology of complex metabolic disease.

  • Open Access

    Impact of signs and symptoms of dry eye disease on health-related quality of life: a cross-sectional population study among older adults

    by Ulla Aapola, Paula Mosallaei, Janika Nättinen, Ilona Suurkuukka, Jaakko Tuomilehto, Sirkka Keinänen-Kiukaanniemi, Jouko Saramies, Hannu Uusitalo

    Purpose: To assess the relationship between quality of life (QoL) and ocular surface health within a Finnish population-based cohort. Methods: A cross-sectional study involved 601 individuals born between the years 1933–1956. Ocular surface health and dry eye disease (DED) were clinically evaluated using several diagnostic tests. Participants completed the Ocular Surface Disease Index (OSDI), QoL assessment with the 15D and Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), and the Beck’s Depression Inventory (BDI-II) questionnaires. Various statistical methods were employed to explore the associations between QoL, ocular surface health, and sex disparities. Results: DED had negative impact on QoL in all participants, and especially in women. Adjusted for comorbidities, DED doubled the odds of worse health-related QoL (15D: OR = 2.31 [95% CI: 1.24–4.31, p < 0.01]) and mental health (SF-36 MCS and BDI-II: OR = 2.08 [95% CI: 1.04–4.16, p < 0.05]). Noninvasive tear break-up time (NIBUT) correlated with all QoL scores. In women, the most significant clinical signs correlating with low QoL were NIBUT (15D: r = 0.20, p = 0.002; SF-36 MCS: r = 0.18, p = 0.026), and conjunctival staining (15D: r=-0.19, p = 0.004; BDI-II: r = 0.27, p < 0.001), whereas in men, blepharitis correlated with depression score (BDI-II: r = 0.20, p = 0.036). High OSDI was associated with worse QoL in women, but not in men. Conclusion: This first population-based study assessing general QoL data with objective clinical measures of DED indicated that among elderly population, both symptoms and signs of DED independently impacted different aspects of QoL. In addition, significant sex-differences in these associations were observed and should be considered both in research settings and when assessing and treating people with DED.


  • Erectile dysfunction as a predictive indicator of asymptomatic diabetes and prediabetes

    by Sebastian Becker, Kadri Suija, Antti Valpas, Markku Koiranen, Juha Auvinen, Hannu Uusitalo, Esko Hussi, Sirkka Keinänen-Kiukaanniemi, Jaakko Tuomilehto, Jouko Saramies


  • Open Access

    Elevated One-Hour Post-Load Glucose Is Independently Associated with Albuminuria: A Cross-Sectional Population Study

    by Anni Saunajoki, Juha Auvinen, Aini Bloigu, Jouko Saramies, Jaakko Tuomilehto, Hannu Uusitalo, Esko Hussi, Henna Cederberg-Tamminen, Kadri Suija, Sirkka Keinänen-Kiukaanniemi, et al.

    The purpose of this study was to examine and compare the associations between albuminuria and fasting (FPG), 1 h post-load (1 h PG) and 2 h post-load plasma glucose (2 h PG) in an oral glucose tolerance test (OGTT). A total of 496 people free of known diabetes (mean age 72 years) participated in the examinations including the OGTT with plasma glucose measurements at 0, 1, and 2 h and levels of HbA1c. Albuminuria was determined by the urinary albumin-to-creatinine ratio and was defined as ≥3.0 mg/mmol. Compared with those without albuminuria, participants with albuminuria had significantly higher 1 h PG and 2 h PG levels, but not FPG or HbA1c levels. An elevated 1 h PG increased the estimated odds ratio of albuminuria more than three times in people with prediabetic 1 h PG (8.6–11.5 mmol/L: OR 3.60; 95% CI 1.70–7.64) and diabetic 1 h PG (≥11.6 mmol/L: OR 3.05; 95% CI 1.29–7.23). After adjusting for blood pressure and age, the association of elevated 1 h PG with albuminuria remained significant. Prediabetic or diabetic FPG, 2 h PG, or HbA1c did not have a statistically significant association with albuminuria. These findings suggest that 1 h PG seems to be the best glycemic parameter and is useful in recognizing persons with an elevated risk of early kidney disease due to hyperglycemia.


  • Open Access

    A Natural History of Erectile Dysfunction in Elderly Men: A Population-Based, Twelve-Year Prospective Study

    by Jouko Saramies, Markku Koiranen, Juha Auvinen, Hannu Uusitalo, Esko Hussi, Sebastian Becker, Sirkka Keinänen-Kiukaanniemi, Jaakko Tuomilehto, Kadri Suija

    There is a wide variation in the development and course of erectile dysfunction (ED) in men, which confirms the need for prospective studies. We conducted a cross-sectional analysis among the general male population at the baseline (n = 359) and in a follow-up survey (n = 218) 12 years later. The prospective 12-year study included 189 men. ED was assessed using the International Index of Erectile Function questionnaire. The mean age of the participants was 62.0 years at the baseline, while at the 12-year follow-up it was 71.6 years. The crude prevalence of ED was 61.6% at the baseline and 78.9% at the follow-up, and the prevalence tended to increase with age. All of the men aged 75 years or more had at least mild ED. The incidence of ED in every thousand person years was 53.5. A total of 54.5% of the men experienced ED progression, while 39.2% reported no changes in erectile function, and 6.3% experienced ED regression during the 12-year study. The likelihood of ED progression was higher in the older compared with younger age group (odds ratio, OR 5.2 (95% CI: 1.1–26.2)), and the likelihood of ED regression was lower among men with increased depression symptoms (OR 0.3 (95% CI: 0.1–0.6)) and among men with a decreased interest in their sexual life (OR 0.1 (95% CI: 0.0–0.6)). Lifestyle factors such as the consumption of alcohol and smoking were not significantly associated with ED.


  • 22-year trends in dysglycemia and body mass index: A population-based cohort study in Savitaipale, Finland

    by Jouko Saramies, Markku Koiranen, Juha Auvinen, Hannu Uusitalo, Esko Hussi, Henna Cederberg, Sirkka Keinänen-Kiukaanniemi, Jaakko Tuomilehto